Seres Therapeutics Announces Board and Officer Changes
Ticker: MCRB · Form: 8-K · Filed: Feb 6, 2025 · CIK: 1609809
| Field | Detail |
|---|---|
| Company | Seres Therapeutics, Inc. (MCRB) |
| Form Type | 8-K |
| Filed Date | Feb 6, 2025 |
| Risk Level | low |
| Pages | 3 |
| Reading Time | 3 min |
| Key Dollar Amounts | $0.001, $45,000, $7,500, $0 |
| Sentiment | neutral |
Sentiment: neutral
Topics: governance, executive-compensation, board-changes
Related Tickers: MCRB
TL;DR
Seres Therapeutics (MCRB) filed an 8-K detailing board and executive changes effective Feb 4, 2025.
AI Summary
Seres Therapeutics, Inc. announced on February 4, 2025, changes in its board of directors and executive compensation. Specifically, the company elected new directors and appointed new officers, alongside adjustments to their compensatory arrangements. The filing details these changes as of February 4, 2025.
Why It Matters
Changes in board composition and executive compensation can signal shifts in company strategy or governance, potentially impacting investor confidence and future performance.
Risk Assessment
Risk Level: low — This filing reports routine corporate governance changes and does not involve significant financial transactions or operational disruptions.
Key Numbers
- 001-37465 — SEC File Number (Identifies the company's filing history with the SEC.)
- 27-4326290 — IRS Employer Identification No. (Company's tax identification number.)
Key Players & Entities
- Seres Therapeutics, Inc. (company) — Registrant
- February 4, 2025 (date) — Date of earliest event reported
- February 6, 2025 (date) — Filing date
- Delaware (jurisdiction) — State of incorporation
- 200 Sidney Street - 4th Floor, Cambridge, MA 02139 (address) — Principal Executive Offices
FAQ
What specific changes were made to the board of directors?
The filing indicates the election of directors as an item of information, but does not specify the names of newly elected directors or any departing directors in the provided text.
Were there any changes in executive officer positions?
Yes, the filing lists 'Appointment of Certain Officers' as an item of information, suggesting changes in executive positions.
What is the effective date of these reported changes?
The earliest event reported is dated February 4, 2025.
What is the company's principal executive office address?
The company's principal executive offices are located at 200 Sidney Street - 4th Floor, Cambridge, MA 02139.
What is the significance of the 'Compensatory Arrangements of Certain Officers' item?
This item indicates that the filing will disclose details regarding the compensation plans or agreements for specific officers of Seres Therapeutics, Inc.
Filing Stats: 783 words · 3 min read · ~3 pages · Grade level 10.9 · Accepted 2025-02-06 08:00:21
Key Financial Figures
- $0.001 — ich registered Common stock, par value $0.001 per share MCRB The Nasdaq Stock Mar
- $45,000 — ectors, including an annual retainer of $45,000, an annual retainer for service on the
- $7,500 — e and Clinical Development Committee of $7,500 and an initial award of an option to pu
- $0 — al Award has an exercise price equal to $0.8056, the closing price per share of th
Filing Documents
- d890486d8k.htm (8-K) — 25KB
- 0001193125-25-021345.txt ( ) — 142KB
- mcrb-20250204.xsd (EX-101.SCH) — 3KB
- mcrb-20250204_lab.xml (EX-101.LAB) — 17KB
- mcrb-20250204_pre.xml (EX-101.PRE) — 11KB
- d890486d8k_htm.xml (XML) — 3KB
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. SERES THERAPEUTICS, INC. Date: February 6, 2025 By: /s/ Thomas J. DesRosier Name: Thomas J. DesRosier Title: Executive Vice President and Chief Legal Officer